{"filings":[{"id":836040,"accession_number":"0001104659-26-070173","cik":1971387,"company_name":"Liminatus Pharma, Inc.","ticker":"LIMN","form_type":"8-K","filed_at":"2026-06-03T21:14:06+00:00","items":["1.01","3.02","3.03","8.01","9.01"],"status":"ready","headline":"Liminatus Pharma raises $1.86M via warrant exercise inducement, issues new warrants for 20.7M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$1.86M from exercise of 10.344M existing warrants at reduced exercise price of $0.18 per share.","Issued new unregistered warrants to purchase up to 20.688M common shares at $0.18, exercisable only after stockholder approval.","New warrants expire five years from stockholder approval date; resale registration to be filed within 20 days.","Maxim Group LLC acted as financial advisor, receiving 8% cash fee on gross proceeds.","Net proceeds from the exercise will be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8077973.886516169,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":696518,"accession_number":"0001104659-26-066974","cik":1971387,"company_name":"Liminatus Pharma, Inc.","ticker":"LIMN","form_type":"8-K","filed_at":"2026-05-27T20:30:41+00:00","items":["3.01","9.01"],"status":"ready","headline":"Liminatus Pharma receives Nasdaq delisting notice; appeals filed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On May 20, 2026, Nasdaq notified Liminatus Pharma it failed to regain compliance with $50M MVLS and $15M MVPHS requirements.","Trading suspension of common stock (LIMN) and warrants (LIMNW) set for May 29, 2026 unless appeal filed by May 27, 2026.","On May 26, 2026, Company requested a hearing before Nasdaq Hearings Panel, which stays delisting pending hearing.","Company previously disclosed non-compliance on Nov 19, 2025 and had 180-day cure period ending May 18, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":8077973.886516169,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":556478,"accession_number":"0001104659-26-064585","cik":1971387,"company_name":"Liminatus Pharma, Inc.","ticker":"LIMN","form_type":"8-K","filed_at":"2026-05-20T21:00:24+00:00","items":["1.01","9.01"],"status":"ready","headline":"Liminatus Pharma to acquire InnocsAI in stock merger valued at ~$320M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["1.6B shares at $0.20/share ($320M aggregate) plus contingent value rights of 20% of future net proceeds from asset sale.","Assets include CAR-T pipeline: IBC101 (Phase 1/2a in Korea for DLBCL) and preclinical INC101 for solid tumors.","CEO Chris Kim also controls Valetudo Therapeutics LLC, a member of InnocsAI, making the transaction a related-party deal.","Closing targeted by Dec 31, 2026, subject to stockholder approvals and other customary conditions.","Liminatus to file a registration statement/proxy statement for the stockholder vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8077973.886516169,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111419,"accession_number":"0001104659-26-023467","cik":1971387,"company_name":"Liminatus Pharma, Inc.","ticker":"LIMN","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Liminatus Pharma reduces stockholder quorum requirement from majority to one-third","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved bylaw amendment reducing quorum from majority to one-third of voting power.","Amendment effective immediately upon Board adoption on February 27, 2026.","Bylaw amendment to be submitted for stockholder ratification at next annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":8077973.886516169,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111418,"accession_number":"0001104659-26-017134","cik":1971387,"company_name":"Liminatus Pharma, Inc.","ticker":"LIMN","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Liminatus Pharma prices $4.0M public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 13.8M shares/pre-funded warrants and warrants for up to 20.7M shares at combined $0.29 per unit.","Gross proceeds ~$4.0M; net proceeds ~$3.46M after placement agent fees and expenses.","Warrants exercisable immediately at $0.29 per share, expire 5 years from issuance.","Placement agent Maxim Group LLC receives 8% cash fee, $100K expense reimbursement, and 690,650 warrant shares at $0.319.","Directors and officers subject to 180-day lock-up; company restricted from certain equity issuances for 180 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8077973.886516169,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111417,"accession_number":"0001104659-26-012016","cik":1971387,"company_name":"Liminatus Pharma, Inc.","ticker":"LIMN","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Liminatus Pharma issues 4M shares to settle $7.5M default judgment, dismisses lawsuits","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Issued 4,000,000 shares to Clear Street LLC in exchange for surrender of 805,377 warrants.","Settles default judgment of $7.5M plus approximately $515K interest from September 2025.","Dismisses two federal lawsuits: Central District of California and Southern District of New York.","Unregistered issuance under Section 3(a)(9) of the Securities Act; no commissions paid."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8077973.886516169,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111416,"accession_number":"0001104659-26-006619","cik":1971387,"company_name":"Liminatus Pharma, Inc.","ticker":"LIMN","form_type":"8-K","filed_at":"2026-01-26T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Liminatus Pharma receives Nasdaq bid price deficiency notice; 180 days to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency notice on Jan 15, 2026 for failing to maintain $1 minimum bid price for 30 consecutive business days.","Has 180 calendar days, until July 14, 2026, to regain compliance by achieving $1 closing bid for 10 consecutive days.","If non-compliant after period, may seek additional time; reverse split must be completed 10 business days before deadline.","Common stock continues trading under symbol LIMN during compliance period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8077973.886516169,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128022,"accession_number":"0001104659-25-116049","cik":1971387,"company_name":"Liminatus Pharma, Inc.","ticker":"LIMN","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Liminatus Pharma receives Nasdaq delisting notices for failing MVLS and MVPHS rules","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notices dated Nov 19, 2025: MVLS below $50M and MVPHS below $15M for 30 consecutive business days.","Company also fails alternative standard under Rule 5450(b)(3)(A) (total assets/revenue each <$50M).","180-day compliance period until May 18, 2026 to regain compliance; stock continues trading under LIMN.","If not compliant by deadline, Nasdaq will issue delisting notice; Company may appeal or transfer to Capital Market.","Management working to regain compliance but no assurance of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8077973.886516169,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144802,"accession_number":"0001104659-25-082579","cik":1971387,"company_name":"Liminatus Pharma, Inc.","ticker":"LIMN","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Liminatus Pharma receives Nasdaq delinquency notice for late Q2 10-Q filing; has 60 days to submit compliance plan","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Liminatus on Aug 22, 2025 of non-compliance with Listing Rule 5250(c)(1) due to delayed Form 10-Q for period ended June 30, 2025.","Company has 60 days, until Oct 21, 2025, to submit a plan to regain compliance; Nasdaq may grant extension to Feb 16, 2026 if plan accepted.","Common stock (LIMN) continues to trade on Nasdaq; no immediate delisting effect.","Liminatus is a pre-clinical stage biopharma developing immune-modulating cancer therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8077973.886516169,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144801,"accession_number":"0001104659-25-078577","cik":1971387,"company_name":"Liminatus Pharma, Inc.","ticker":"LIMN","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Liminatus Pharma provides IBA101 strategic update targeting PD-1/L1 patent cliff partnership opportunities","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["IBA101 is a CD47 mAb designed to avoid RBC/platelet binding, eliminating cytopenia that derailed Hu5F9 and lemzoparlimab.","Preclinical data shows IBA101 + anti-PD-1 combination produces synergistic anti-tumor response with favorable safety.","Company claims it is the only U.S.-based firm developing a CD47 blocker with a validated safety profile.","PD-1/L1 inhibitors Keytruda (Merck) and Opdivo (BMS) face core patent expiry by 2028; others (Tecentriq, Imfinzi, Libtayo) by 2030.","Strategy positions IBA101 as a patent-protected synergistic partner to extend PD-1/L1 franchise lifecycles."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":8077973.886516169,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144800,"accession_number":"0001104659-25-068670","cik":1971387,"company_name":"Liminatus Pharma, Inc.","ticker":"LIMN","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Liminatus Pharma exchanges 1M warrants for 350K shares with Alta Partners","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company issued 350,000 shares of common stock to Alta Partners in exchange for surrender and cancellation of 1,000,000 warrants.","No commission or other remuneration was paid in connection with the exchange.","Shares were issued in reliance on the Section 3(a)(9) exemption from registration.","The transaction reduces potential dilution from outstanding warrants by 650,000 shares on a net basis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8077973.886516169,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144799,"accession_number":"0001104659-25-067444","cik":1971387,"company_name":"Liminatus Pharma, Inc.","ticker":"LIMN","form_type":"8-K","filed_at":"2025-07-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Liminatus Pharma appoints Philip Lemons and Richard Baek to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 5 to 6 members with appointment of Lemons and Baek effective July 10, 2025.","Philip Lemons, 54, brings clinical R&D expertise; serves as Chief Business Officer at ICE Global Consulting.","Richard Baek, 33, brings financial oversight and regulatory compliance; VP Finance at Studio City PXL.","No arrangements or transactions with the company requiring disclosure under Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":8077973.886516169,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144798,"accession_number":"0001104659-25-065663","cik":1971387,"company_name":"Liminatus Pharma, Inc.","ticker":"LIMN","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Liminatus Pharma forms consortium for pancreatic cancer blood diagnostic with >95% sensitivity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Signed MOU with Samda Biolab and INNOCS AI to develop a blood-based diagnostic kit for early pancreatic cancer detection.","Combined CA19-9 and INNOCS platform achieved >95% sensitivity and >99% specificity in a 1,086-subject cohort.","Liminatus will lead regulatory filings with FDA and KMFDS upon commercialization phase.","Global pancreatic cancer diagnostics market projected at $3B by 2026; blood-based segment >$700M.","Consortium to leverage AI, biomarker platform, and Liminatus's regulatory/commercial infrastructure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8077973.886516169,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163208,"accession_number":"0001104659-25-062058","cik":1971387,"company_name":"Liminatus Pharma, Inc.","ticker":"LIMN","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Liminatus Pharma advances IBA101 CD47 inhibitor toward IND submissions in H2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed GLP toxicology studies at Charles River; no clinically meaningful hemoglobin or platelet reductions in primates.","Plans simultaneous IND submissions to FDA and Korea's MFDS in H2 2026; site activations and patient screening start early 2027.","Partnered with Dr. Se-Hoon Lee at Samsung Medical Center for Phase 1 trial in NSCLC, including 3+3 dose-escalation and PD-1/PD-L1 combination arms.","Preclinical combination data with PD-1/PD-L1 inhibitors showed increased complete response rates versus monotherapy.","Engineered epitope selectivity and Fc modifications designed to avoid anemia/thrombocytopenia that halted earlier CD47 programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8077973.886516169,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163207,"accession_number":"0001104659-25-061875","cik":1971387,"company_name":"Liminatus Pharma, Inc.","ticker":"LIMN","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Liminatus Pharma provides update on lead asset IBA101; IND filing H2 2025","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["IBA101 is a next-generation CD47 blockade designed to avoid anemia and thrombocytopenia seen with first-generation drugs.","Preclinical data show IBA101 plus PD-1/PD-L1 inhibitors gave 2-3x higher complete response rates vs monotherapy.","IND preparation begins H2 2025 with simultaneous submissions to U.S. FDA and Korea MFDS planned.","Phase 1 first-in-human study in advanced solid tumors (starting with NSCLC) expected to launch in late 2026.","Company completed SPAC merger with IRIS Acquisition Corp. and began trading on Nasdaq in May 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8077973.886516169,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163206,"accession_number":"0001104659-25-056421","cik":1971387,"company_name":"Liminatus Pharma, Inc.","ticker":"LIMN","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Liminatus Pharma receives and resolves Nasdaq non-compliance for late 10-Q filing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on May 29, 2025, for non-compliance with Listing Rule 5250(c)(1) due to delayed Form 10-Q.","Filed the overdue Form 10-Q for Q1 2025 on June 2, 2025.","Nasdaq confirmed on June 3, 2025, that the company regained compliance; matter is closed.","Pre-clinical biotech (LIMN) focuses on immune-modulating cancer therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":8077973.886516169,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163203,"accession_number":"0001104659-25-055078","cik":1971387,"company_name":"Liminatus Pharma, Inc.","ticker":"LIMN","form_type":"8-K/A","filed_at":"2025-06-02T23:59:59+00:00","items":["2.01","9.01","1.01","5.02","3.02","4.01"],"status":"ready","headline":"Liminatus Pharma completes de-SPAC business combination, files Q1 2025 financials","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Business combination closed April 30, 2025; combined company trades on Nasdaq as LIMN and LIMNW.","Public stockholders redeemed 59,844 shares for ~$702k (~$11.74/share).","Liminatus is pre-revenue, pre-clinical; net loss of $3.5M in FY2024, $5.0M in FY2023, accumulated deficit $28.7M.","Amendment adds unaudited Q1 2025 financial statements of Liminatus and Iris; specific results not summarized in filing.","Enterprise value of Liminatus set at $175M; 17,500,000 common shares issued to former Liminatus securityholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8077973.886516169,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163205,"accession_number":"0001104659-25-045127","cik":1971387,"company_name":"Liminatus Pharma, Inc.","ticker":"LIMN","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["1.01","2.01","5.02","3.02","4.01","9.01","3.03","5.01","5.03","5.05","5.06","7.01","8.01"],"status":"ready","headline":"Liminatus Pharma completes de-SPAC merger, receives $15M PIPE, begins Nasdaq trading","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed de-SPAC merger with Iris Acquisition Corp; issued 17.5M shares at $10/share ($175M equity value) to Liminatus securityholders.","Concurrent $15M PIPE investment (1.5M shares at $10) from accredited investor.","Sponsor forfeited 4.18M private placement warrants; 59,844 public shares redeemed for ~$702k.","Liminatus Pharma, a pre-clinical CD47 checkpoint inhibitor developer, reported FY2024 net loss of $3.5M, accumulated deficit $28.7M.","Common stock (LIMN) and warrants (LIMNW) began trading on Nasdaq May 1, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":8077973.886516169,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163204,"accession_number":"0001104659-25-042489","cik":1971387,"company_name":"Liminatus Pharma, Inc.","ticker":"LIMN","form_type":"8-K12B","filed_at":"2025-04-30T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Liminatus Pharma completes business combination with Iris Acquisition Corp; trades as LIMN","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Combined company Liminatus Pharma, Inc. begins trading on Nasdaq under LIMN and LIMNW on May 1, 2025.","Liminatus develops anti-CD47 monoclonal antibody IBA101 for advanced solid cancers including non-small cell lung cancer.","Leadership: CEO Chris Kim, CFO Scott Dam, CSO Byong C. Yoo.","Business Combination approved at Iris stockholders meeting on March 4, 2025.","Advisors: Holland & Knight for Iris, Loeb & Loeb for Liminatus, Raymond James."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8077973.886516169,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}